Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Stage III Lung Non-Small Cell Cancer AJCC v7 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Neoplasms 1Mouth Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 14Magnetic Resonance Spectroscopy 11Taxes 9Biopsy 9veliparib 7Paclitaxel 7Carboplatin 7pembrolizumab 3olaparib 3Cyclophosphamide 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone 3talazoparib 2eribulin 2entinostat 2cediranib 2Radiotherapy 2Radiation 2Platinum 2Nivolumab 2Irinotecan 2Immunoglobulin G 2Gemcitabine 2Doxorubicin 2Disulfides 2Cisplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 21,2-diaminocyclohexaneplatinum II citrate 2tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Triple Negative Breast Neoplasms × fluoromisonidazole × Clear all
NCT02498613 2026-05-01

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
122 enrolled 16 charts
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡